Stephen Henry

As the CEO and Managing Director of Kode Biotech, Stephen Henry is at the forefront of innovative biotechnological advancements, spearheading a group of companies that includes Kode Biotech, Kode Biotech Materials, and GlycoNZ. Under his leadership, Kode Biotech has emerged as a pioneer in the field of surface modification technology, which has transformative implications for both biological and non-biological applications. Stephen’s vision for Kode Technology as a breakthrough innovation is driven by his deep expertise in protein chemistry, cell biology, and drug development, positioning the company to address critical challenges in therapeutics and diagnostics.

One of the key projects currently under Stephen's guidance is the development of versatile surface modification techniques that allow for the rapid and controllable alteration of surface functionalities. This technology has broad applications, including enhancing the efficacy of drug delivery systems, improving the performance of medical devices, and advancing research in biomarker discovery. Stephen's commitment to research and development (R&D) is evident in Kode Biotech's collaborative efforts with academic institutions and industry partners, aiming to translate cutting-edge research into practical solutions that can significantly impact patient care.

In addition to his technical acumen, Stephen is known for his ability to navigate the complexities of technology transfer and clinical development, ensuring that innovative ideas are effectively brought to market. His passion for biological design and unwavering courage to challenge the status quo drive Kode Biotech's mission to revolutionize the biotechnology landscape, making him a respected leader and visionary in the industry.